MZMeng Zhao

Meng Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meng Zhao has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Protective effects of biomimetic Cu-Zn-MOF against DOX-Induced cardiotoxicity through inhibiting oxidative stress and ferroptosis

    by Jian Wang, Meng Zhao, Jian Zhang, Xiaoyan Zhang, Hongming Zhu, Changnan Wang, Song Zhang

    Doxorubicin (DOX), a member of the anthracycline family, is widely recognized as an effective chemotherapeutic agent for cancer treatment. However, its cli


  • Open Access

    Computational Discovery of Aggregation-Mediated Dipeptide Inhibitors Targeting PHLDA1 for Cardiovascular Therapy

    by Shujia Liu, Haojin Zhou, Weihua Bian, Kanghui Huan, Meng Zhao, Jiaqi Wang

    Cardiovascular disease remains a leading cause of global mortality, underscoring the urgent need for novel therapeutic strategies. This study focuses on the pleckstrin homology-like domain family A member 1-encoded protein (PEP), a regulator of cardiomyocyte apoptosis and a promising yet underexplored therapeutic target. Leveraging an integrated computational approach, we combined AlphaFold3-based structure prediction with extensive molecular dynamics simulations to characterize PEP's dynamic architecture and identify high-affinity dipeptide inhibitors. Our results reveal that PEP possesses significant intrinsic disorder, with molecular dynamics simulations refining its conformation and highlighting force field-dependent behaviors, particularly the superior performance of CHARMM-class force fields in preserving functional secondary structures. High-throughput screening of phenylalanine-based dipeptides identified FF as the strongest binder, exhibiting a unique aggregation-mediated binding mechanism that engages both primary and secondary sites on PEP through multivalent interactions. Concentration-dependent simulations further confirmed the robustness of FF binding and revealed residue-specific interaction hotspots. Notably, we demonstrate that low-confidence regions in AF3 predictions (pLDDT <50) frequently participate in functional binding, challenging the conventional lock-and-key paradigm. These findings not only establish PEP as a tractable drug target but also provide a novel framework for designing aggregation-prone peptide therapeutics against cardiovascular diseases.


  • Open Access

    In Silico Screening of Peptide Inhibitors of PHLDA1-Encoded Protein Targeting Cardiovascular Diseases

    by Shujia Liu, Haojin Zhou, Meng Zhao, Jiaqi Wang

    The PHLDA1-encoded protein (PEP) is a pivotal regulator of cardiomyocyte apoptosis and a promising therapeutic target for cardiovascular diseases. Leveraging in silico approaches, we characterized PEP's structure using AlphaFold3 (AF3) and refined it via molecular dynamics (MD) simulations with various force fields. Kinetic and thermodynamics analysis further confirmed revealed that the Amber99 force field induced the most significant structural change, with the most significant decrease in radius of gyration and lowest potential energy. High-throughput screening of 20 phenylalanine-based dipeptides (FA-FY) revealed sequence-dependent binding to PEP, with FF, FH, FP, and FY exhibiting the maximum count of binders (11, 7, 6, and 6, respectively). Key residues (e.g., L55, C60, E142, E89) formed a continuous binding groove, while FF dipeptides demonstrated cooperative aggregation-enhanced binding. Notably, low-pLDDT regions (< 50) frequently participated in ligand interactions, challenging the rigid "lock-and-key" paradigm and underscoring the role of intrinsic disorder in binding. this work establishes PEP as a tractable target for dipeptide inhibitors and provides a computational framework for designing peptide-based therapeutics against cardiac injury.